Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

BACKGROUND: The median age at renal cell carcinoma (RCC) diagnosis is 64 years. However, few studies have assessed the real-world time on treatment (TOT), health resource utilization (HRU), costs, or treatment compliance associated with targeted therapy use among patients in this age group with RCC....

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Li, Nanxin, Swallow, Elyse, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397629/
https://www.ncbi.nlm.nih.gov/pubmed/29799328
http://dx.doi.org/10.18553/jmcp.2018.24.6.525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397629/
https://www.ncbi.nlm.nih.gov/pubmed/29799328
http://dx.doi.org/10.18553/jmcp.2018.24.6.525

Ejemplares similares